Home
Funding Areas
About Us
"We are experiencing a paradigm shift in medicin," says Hans Winberg, secretary general of the Leading Healthcare Foundation in Sweden.
"We see however only a few signs of this in our current health care system."
That's why the foundation has teamed up with Diamyd Medical, an immunotherapy company in Sweden, to create an AI-based tool that could help prevent type 1 diabetes in children and young adults.
The tool, called ASSET (AI for Sustainable Prevention of Autoimmunity in the Society), will analyze data from Diamyd Medical's clinical trials and from sources such as the National Diabetes Registry to create an algorithm that can predict a person's risk of developing type 1 diabetes, as well as their likelihood of responding to various treatments, per Diamyd Medical.
"To integrate predictive analytics with targeted immunotherapies like the antigen-specific immunotherapy Diamyd holds the potential to prevent symptomatic disease," CEO Ulf Hannelius says in a press release.
"This requires strong engagement with relevant stakeholders, and the ASSET partnership provides the nescessary platform to bring this vision to fruition."
Diamyd Medical is currently testing its vaccine, called Diamyd, on children and young adults with recently diagnosed type 1 diabetes.